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Background: In order to improve the treatment outcome in multiple sclerosis, it is important 
to document the factors that influence adherence to therapy. The purpose of this study was to 
determine patient perceptions and awareness of multiple sclerosis and its treatment, treatment 
adherence, and impact on quality of life and daily living.
Methods: This was a cross-sectional observational study performed in France. Each participat-
ing neurologist included the first three patients with relapsing-remitting multiple sclerosis who 
consulted after the start of the study. Data on clinical features were collected from a physician 
questionnaire and on disease and treatment perception and on quality of life from a patient 
autoquestionnaire.
Results: A total of 175 neurologists entered 202 patients in the study. The mean duration of 
disease was 8.0 ± 7.0 years, and immunomodulatory treatment had been administered for a 
mean duration of 3.0 ± 2.0 years. A total of 166 patients (82.2%) were treated with interferon-β 
preparations and 36 patients (17.8%) with glatiramer acetate. Eighty-five patients (42.1%) 
reported missing their injections from time to time and 36 patients (17.8%) reported “drug 
holidays”. The most frequently given reason for nonadherence was forgetfulness (38.7% of cases). 
Eighty-six patients (42.6%) and 70 patients (34.7%) claimed to be well informed about their 
disease and treatment, respectively. Adherence was significantly higher in well informed patients 
(P = 0.035). The majority of patients (176 patients, 87.1%) intended continuing their current 
treatment and 49.5% considered that their current treatment might reduce relapses. The most 
frequently reported side effect was muscle pain (124 patients, 61.4%).
Conclusion: Patient understanding of treatment for disease enhances treatment adherence. 
Greater patient involvement in disease management requires better communication between 
physicians and their patients.
Keywords: multiple sclerosis, patient adherence, quality of life
Introduction
Multiple sclerosis is a common, chronic inflammatory disease of the central nervous 
system, which most frequently appears in early adulthood and is more frequent in 
women than in men. Given that multiple sclerosis usually affects people in the most 
active and productive phase of their lives, and since the frequency and severity of 
attacks are largely unpredictable, the impact of the disease on activities of daily living, 
functioning, and quality of life can be important.1–3
Disease management in multiple sclerosis involves treatment of acute 
relapses, use of disease-modifying treatments to prevent relapses, and symptom 
  management.   Disease-modifying treatments, of which four are currently licensed for 
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the   first-line treatment of relapsing-remitting multiple   sclerosis 
(three interferon-β preparations and glatiramer acetate), have 
been demonstrated in large randomized clinical trials to 
reduce relapse rates, improve magnetic resonance imaging 
markers of disease activity, and in some cases to slow disease 
progression.4–7 These treatments, which are all administered 
by injection, need to be taken over the long term, perhaps life-
long, because interruption of treatment leads to recrudescence 
of disease activity.8 However, many previous studies have 
demonstrated that adherence to injectable immunomodulatory 
therapies is poor.9 For example, in a cohort of 308 patients in 
Germany followed prospectively for 2 years after treatment ini-
tiation,10 25 patients (8.1%) discontinued in the first 6 months 
and a further 68 (22.1%) had stopped their treatment at the end 
of 2 years of follow-up.10 In an Irish cohort, 28% of patients 
starting on interferon-β had discontinued by 5 years.11 Even 
higher discontinuation rates have been reported elsewhere, ie, 
41.1% of patients treated with interferon-β 1b after 3 years in 
a large prospective Italian cohort12 and 38.9% after 3 years in 
a retrospective chart review in Canada.13
Strategies to improve treatment outcome in multiple scle-
rosis thus need to ensure optimal adherence to therapy.14,15 
In order to do this, it is important to understand the relative 
importance of the different factors that influence adherence. 
To this end, we have performed a survey in order to investi-
gate patient-reported perceptions of disease and treatment. 
The principal objectives of this study were to describe the 
perceived benefits and limitations of current immunomodula-
tory treatments for multiple sclerosis, treatment adherence, 
impact on quality of life and daily living, and treatment 
expectations and needs.
Methods
Study design
This was a cross-sectional observational survey conducted 
in France between April 24 and May 31, 2006. The survey 
was implemented by TNS SOFRES, an international polling 
institute. A letter was sent to the 1118 neurologists practic-
ing in France inviting them to participate in the survey, of 
whom 175 (15.7%) agreed to take part. It should be noted 
that French legislation on medical studies and surveys 
requires that the protocol be proposed to all specialists in 
the   country, regardless of whether they see the target patient 
group or not. In the case of multiple sclerosis, almost all 
non-institutionalized patients are managed in a national 
network of 44 centers (Observatoire Français de la Sclérose 
en Plaques; http://www.edmus.org/en/proj/observatoire.html) 
involving around 400 neurologists.
Population
Each participating neurologist was expected to include the 
first three patients with relapsing-remitting multiple sclerosis 
who consulted after the start of the study and who agreed to 
take part in the survey. Inclusion criteria were a diagnosis of 
relapsing-remitting multiple sclerosis, an Expanded Disability 
Status Scale score (EDSS) score # 5.5, and prescription of an 
immunomodulatory treatment for at least 3 months.
Data collection
Data were collected from a physician questionnaire completed 
during the consultation and from a patient auto questionnaire 
which the neurologist gave to the patient to be completed at 
home and sent directly to the company responsible for ana-
lyzing the data in a prepaid envelope. Both questionnaires 
were designed specifically for this study.
The physician questionnaire collected data on the age, 
gender, and clinical features of the patient, and on the treat-
ment used. The number of relapses in the previous 2 years, 
the last available EDSS score, and the time since diagnosis 
were documented. The patient auto questionnaire collected 
information on sociodemographics, disease and treatment 
perceptions, information about multiple sclerosis, involve-
ment in treatment decisions, adherence, side effects, and 
impact of treatment on quality of life as well as on patient 
involvement in managing the disease and its treatment. Side 
effects were identified on a 13-item checklist (11 identified 
side effects, “other side effects”, and “no side effects”) relat-
ing to side effects that the patient considered to be attribut-
able to their treatment, which they had experienced in the 
previous 3 months. With respect to adherence, patients were 
asked if they had ever skipped injections, whether they had 
skipped injections in the previous 3 months and, if so,   how 
many, whether they had ever stopped their treatment and, if 
so, for how long. Reasons for skipping and stopping were 
also investigated. The impact of treatment on quality of life 
was measured using a seven-item scale. The items related to 
physical activity, morale/mood, social life or leisure pursuits, 
professional activity, relationships/sex life, family and emo-
tional life, and overall quality of life. Each item was graded 
on an 11-point Likert scale (0, very considerable negative 
impact; 10, no impact).
Psychometric evaluation of quality  
of life score
Because the quality of life scale had not been previously 
validated, we performed a preliminary evaluation of its 
psychometric properties. This included determination of the 
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Cronbach’s α coefficient of internal consistency, pairwise 
evaluation of correlation between the seven items of the scale, 
and factorial analysis using principal component analysis.
Statistical analysis
Univariate statistics were used to describe the results of the 
survey, using the mean and standard deviation for continuous 
variables and numbers and percentages for categorical ones. 
Treatment groups were compared using the Student’s t-test 
for continuous variables and Pearson’s χ² test for categori-
cal variables. The association between adherence and four 
relevant study variables selected a priori by the scientific 
committee (age, information about disease, information 
about treatment, and immunomodulatory drugs prescribed) 
was also evaluated, as well as on-treatment relapse rate. For 
this analysis, non adherence was defined as missing at least 
one injection over the previous 3 months.
Ethical considerations
The survey protocol was submitted for evaluation to 
the national ethics advisory board. They considered that 
participation of patients in the study would not affect their 
medical care, and therefore that it was not necessary to 
obtain ethics committee approval. Patients were provided 
with information on the goals and methods of the study and 
verbal consent was obtained from each patient. The study 
protocol was submitted to the Commission Nationale de 
l’Informatique et des Libertés, responsible for overseeing 
data privacy in France.
Results
Of the 175 neurologists who had agreed to take part, 47% 
were practicing in a hospital setting only, 28% were in 
community practice, and 25% worked in both settings. Of 
these, 84 neurologists (48.0%) recruited at least one patient 
who returned their questionnaire. A total of 202 patients 
completed and returned the questionnaire, and these 
comprised the study population. The demographic and 
clinical features of the study population are summarized 
in Table 1 according to the immunomodulatory treatment 
prescribed. Three quarters of the patients were women 
and the mean age of the sample was 41 years. The mean 
duration of disease was 8.0 ± 7.0 years, and 42 patients 
(20.8%) had been diagnosed less than 3 years previously. 
During the previous 24 months, 32% of the patients had 
not experienced an attack, whereas 61% had experienced 
1–3 attacks. The median EDSS disability score at the last 
evaluation was 2.2 overall, with no significant differences 
between immunomodulatory treatment groups. For most 
patients, the EDSS was determined at the study visit itself; 
the mean interval between the last EDSS evaluation and study 
inclusion was 2.8 months.
immunomodulatory treatments
Most of the patients were being treated with an interferon 
(principally interferon-β 1a by intramuscular injection; 
93 patients, 46%), while 36 patients (17.8%) had been 
prescribed glatiramer acetate (Table 1). The majority of 
patients (n = 156; 77.2%) were taking their first-line therapy, 
although the proportion of patients currently treated with 
glatiramer acetate as a second-line therapy (18 patients; 
50.0%) was higher than the corresponding proportion 
for patients treated with an interferon-β preparation 
(28 patients; 83.0%). Only three patients currently treated 
with an interferon had previously received glatiramer acetate. 
The mean duration of treatment ranged from 1.1 years 
for glatiramer acetate to 4.0 years for interferon-β 1a by 
intramuscular injection.
With respect to the choice of treatment, the patients 
followed the advice of their neurologist in the majority of cases 
(112 patients; 55.4%). In 81 cases (40.1%), the neurologist 
proposed a choice of treatments to the patient, whereas nine 
patients (4.5%) requested a specific medication from their 
  neurologist. For the 90 patients who were involved in the choice 
of treatment, the primary consideration was most frequently 
efficacy (38 patients; 42.2%), followed by injection frequency 
(25 patients; 27.8%), anticipated side effects (14 patients; 
15.6%), and whether they could get help with their injections 
(11 patients; 5.4%). Somewhat over half of the patients were 
performing their own injections (n = 114; 56.4%), whereas 
55 (27.2%) were receiving their injections from a family 
member or friend and 27 (13.4%) from a nurse.
The current immunomodulatory treatment had been 
administered for a mean period of 3.0 ± 2.0 years, with 
47 patients (23.3%) having been prescribed the same treat-
ment for 5 years or more and 35 (17.3%) for less than one 
year. Sixty-one patients (30.2%) had already switched 
between different immunomodulatory treatments. The switch 
was initiated by the neurologist in 45 cases and requested 
by the patient in 12 cases. The main reasons reported for 
the switch was poor tolerability (33 patients) and perceived 
lack of efficacy (28 patients). Eight patients reported having 
switched because they wanted to try a new treatment and 
six patients because they wanted to use a more convenient 
treatment. The adverse events most often reported as   having 
led to a change in treatment were “flu-like” symptoms 
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(19 patients) and injection site reactions (seven patients). Of 
the 61 patients who had switched, 41 were better satisfied 
with their new treatment, whereas four were less satisfied.
With respect to treatment adherence, 85 patients (42.1%) 
reported missing their injections from time to time and 
53 (26.2%) had missed at least one injection in the previous 
3 months. The number of injections missed over this period 
was 1–3 for 44 of these patients, and only nine patients had 
missed more than three injections. The number of patients 
missing at least one injection over the past 3 months was 
higher in younger patients and in patients who considered 
themselves not well informed about their disease (Table 2). 
No such difference in this variable was observed between 
the different treatments, although a trend towards a lower 
proportion of patients missing their injections was observed 
for those using interferon-β 1a. In addition, no association 
was observed between nonadherence and relapses in the 
previous 2 years.
In addition, 36 patients (17.8%) reported that they had 
stopped their treatment for a while. Fourteen patients had 
stopped for less than a week, whereas ten had stopped for 
over one month. Only a minority of patients who skipped 
Table 1 Demographic and clinical features of the survey sample
Interferon-β 1a IM 
(n = 93)
Interferon-β 1a SC 
(n = 32)
Interferon-β 1b SC 
(n = 41)
Glatiramer acetate 
(n = 36)
Total 
(n = 202)
Gender
  Men 18 (19.4%) 11 (34.4%) 9 (22.0%) 12 (33.3%) 50 (24.8%)
  Women 75 (80.6%) 21 (65.6%) 32 (78.0%) 24 (66.7%) 152 (75.2%)
Age (years)
  Mean ± SD 41.8 ± 10.3 40.5 ± 9.9 40.0 ± 10.0 39.1 ± 8.6 40.7 ± 9.9
 , 25 years 4 (4.3%) 1 (3.1%) 2 (4.9%) 1 (2.8%) 8 (4.0%)
  25–34 years 18 (19.4%) 8 (25.0%) 13 (31.7%) 12 (33.3%) 51 (25.2%)
  35–44 years 31 (33.3%) 13 (40.6%) 13 (31.7%) 10 (27.8%) 67 (33.2%)
  45–54 years 30 (32.3%) 6 (18.8%) 10 (24.4%) 12 (33.3%) 58 (28.7%)
  55–64 years 7 (7.5%) 4 (12.5%) 3 (7.3%) 1 (2.8%) 15 (7.4%)
 $ 65 years 3 (3.2%) – – – 3 (1.5%)
Marital status n = 93 n = 32 n = 40 n = 36 n = 201
  Single 19 (20.4%) 5 (15.6%) 8 (20.0%) 8 (22.2%) 40 (19.9%)
  Married 61 (65.6%) 26 (81.3%) 31 (77.5%) 21 (58.3%) 139 (69.2%)
  Widowed 1 (1.1%) – – 1 (2.8%) 2 (1.0%)
  Divorced or separated 12 (12.9%) 1 (3.1%) 1 (2.5%) 6 (16.7%) 20 (10.0%)
Number of children n = 88 n = 26 n = 39 n = 35 n = 188
 0 20 (22.7%) 5 (19.2%) 14 (35.9%) 12 (34.3%) 51 (27.1%)
 1 25 (28.4%) 2 (7.7%) 9 (23.1%) 8 (22.9%) 44 (23.4%)
 2 29 (33.0%) 13 (50.0%) 13 (33.3%) 10 (28.6%) 65 (34.6%)
 $ 3 14 (15.9%) 6 (23.1%) 3 (7.7%) 5 (14.3%) 28 (14.9%)
Employment status n = 91 n = 32 n = 39 n = 34 n = 196
  Employed 71 (78.0%) 20 (62.5%) 32 (82.0%) 26 (76.5%) 149 (76.0%)
  Not in employment 20 (22.0%) 12 (37.5%) 7 (18.0%) 8 (23.5%) 47 (24.0%)
Disease duration
  Mean ± SD 9.0 ± 7.0 8.0 ± 6.1 7.1 ± 8.1 6.1 ± 5.1 8.0 ± 7.0
Treatment duration (years)
  Mean ± SD 4.0 ± 2.1 3.0 ± 2.0 2.1 ± 1.1 1.1 ± 1.0 3.0 ± 2.0
  Median 3.9 3.0 2.5 1.1 2.8
Relapses in previous 24 months n = 93 n = 32 n = 40 n = 36 n = 201
 0 37 (39.8%) 12 (37.5%) 10 (25.0%) 5 (13.9%) 64 (31.8%)
 1 23 (24.7%) 9 (28.1%) 16 (40.0%) 16 (44.4%) 64 (31.8%)
  2 or 3 28 (30.1%) 10 (31.3%) 12 (30.0%) 9 (25.0%) 59 (29.4%)
  4 or 5 3 (3.2%) 1 (3.1%) 2 (5.0%) 5 (13.9%) 11 (5.5%)
 . 5 2 (2.2%) – – 1 (2.8%) 3 (1.5%)
EDSS score at inclusion (mean ± SD) 2.0 ± 1.4 2.5 ± 1.7 2.3 ± 1.5 2.2 ± 1.2 2.2 ± 1.5
  EDSS , 4 78 (83.9%) 20 (62.5%) 33 (80.5%) 32 (88.9%) 163 (80.7%)
  EDSS $ 4 15 (16.1%) 12 (37.5%) 8 (19.5%) 4 (11.1%) 39 (19.3%)
Nonadherence rate 18 (19.4%) 9 (28.1%) 13 (31.7%) 13 (36.1%) 53
Abbreviations: EDSS, Expanded Disability Status Scale; iM, intramuscular; SC, subcutaneous; SD, standard deviation.
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injections (35 of 85 patients) or interrupted treatment 
(nine of 36) reported discussing this with their neurologist 
usually or sometimes.
The reasons most frequently given for skipping or stopping 
treatment were forgetfulness (38.7% of 93 patients stopping or 
skipping) and weariness with injections (28.0%). Side effects 
were mentioned by 14.0% of these patients. Other reasons 
given included travel (21.5%), holidays (7.5%), neurologist 
advice (10.8%), to help not thinking about being ill (8.6%), 
pregnancy (3.2%), and surgery (2.2%). Perceived lack of effi-
cacy does not seem to have been a reason for nonadherence.
Patient information
Patients were asked whether they considered themselves well 
informed about their disease and its treatment. Eighty-six 
patients (42.6%) reported considering that they had been well 
informed about their disease, and 70 (34.7%) reported that 
they had been well informed about their treatment (Table 3). 
The source of information most frequently cited was the 
neurologist, followed by the Internet, general practitioners, 
patient groups, and health care networks (Table 3). Nearly 
half of the patients expressed a desire for more contact with 
their neurologist and general practitioner (Table 3). There 
was much less demand for closer contact with a nurse, 
a pharmacist, or other health care professionals.
Table 2 Adherence to treatment
Variable n Nonadherent P
Age group 
  ,35 years 
  35–44 years 
  $45 years
 
59 
67 
76
 
21 (35.6%) 
19 (18.6%) 
13 (33.0%)
 
0.047
information about disease
  Well informed 
  Not well informed
86 
112
16 (18.6%) 
37 (33.0%)
0.035
information about treatment
  Well informed 
  Not well informed
70 
120
15 (21.4%) 
38 (31.7%)
0.129
Treatment
  interferon-β 1a iM 
  interferon-β 1a SC 
  interferon-β 1b SC 
  Glatiramer acetate
93 
32 
41 
36
18 (19.4%) 
9 (28.1%) 
13 (31.7%) 
13 (36.1%)
0.189
Relapses in previous 24 months
  None 
  One 
  Two or three 
  Four or five 
  More than five
64 
64 
59 
11 
3
16 (25.0%) 
19 (29.7%) 
14 (23.7%) 
2 (18.2%) 
2 (66.7%)
0.473
Notes: Data are presented as the number (%) of nonadherent patients, defined 
as those missing at least one injection over the past 3 months; probabilities are 
calculated with the χ² test.
Abbreviations: SC, subcutaneous; iM, intramuscular.
Table 3 Patient information
i am well informed about my disease 
  Totally agree 
  Partly agree 
  Partly disagree 
  Totally disagree 
  No opinion
 
86 (42.6%) 
90 (44.6%) 
18 (8.9%) 
4 (2.0%) 
4 (2.0%)
i am well informed about my treatment 
  Totally agree 
  Partly agree 
  Partly disagree 
  Totally disagree 
  No opinion
 
70 (34.7%) 
81 (40.1%) 
29 (14.4%) 
10 (5.0%) 
12 (5.9%)
Source of information 
  Neurologist 
  internet 
  General practitioner 
  Patient association 
  Care network 
  Pharmacist 
  Other
 
182 (90.1%) 
89 (44.1%) 
77 (38.1%) 
40 (19.8%) 
20 (9.9%) 
10 (5.0%) 
12 (5.9%)
Desire for more contact 
  With neurologist 
  With general practitioner 
  With nurse 
  With pharmacist 
  With other health care professionals
 
98 (48.5%) 
81 (40.1%) 
27 (13.4%) 
19 (9.4%) 
8 (4.0%)
Social support
Most patients reported that they had informed their 
spouse/partner (n = 166; 82.2%), other family members 
(n = 196; 97.0%), and friends (n = 160; 79.2%) that they had 
multiple sclerosis. Of the 149 patients who were working, 
89 (59.7%) said that they had told their colleagues about 
their disease. None of the patients reported that nobody knew 
about their multiple sclerosis. Some degree of involvement 
of family and friends in managing multiple sclerosis was 
recognized by 172 patients (85.1%), the level of involvement 
being reported as considerable by 68 patients, moderate by 
75 patients, and low by 29 patients.
Perception of treatment
A large majority of patients (n = 176; 87.1%) stated that 
they intended continuing their current treatment until a 
more effective new treatment became available. Only nine 
patients (4.5%) claimed to be considering stopping their 
treatment.
Patients were asked how they thought that their current 
treatment would help them and what had changed since 
starting treatment (Table 4). Around one half (100 patients; 
49.5%) totally agreed that their current treatment would help 
reduce relapses and 35.6% agreed that it would slow disease 
progression. Around one third totally agreed that they lived 
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The most frequently reported were muscle pain 
(124 patients; 61.4%), headache (120 patients; 59.4%), 
post-injection fatigue (113 patients; 55.9%), and flu-like 
states (112 patients; 55.0%). Because the adverse event 
profiles of interferon-β preparations and glatiramer acetate 
are different, a separate analysis was made for each treat-
ment class (Figure 1). The proportion of patients reporting 
post-injection fatigue and flu-like states was significantly 
higher (P , 0.001) in patients using an interferon-β than 
in those using glatiramer acetate. In contrast, injection site 
reactions were more frequently reported by patients using 
glatiramer acetate (P = 0.001). No obvious differences 
were observed in reported side effects between patients 
using different interferon-β preparations (data not shown). 
The patients most frequently discussed these side effects 
with their neurologist (n = 190; 94.1% of cases), either 
spontaneously or when asked. They also discussed them 
with their general practitioner (n = 125; 61.9%) or with 
nurses (n = 62; 30.7%).
Overall, 153 patients (75.7%) said that they had taken 
medication to relieve the side effects of their treatment. This 
was reported less frequently (P , 0.001) by patients taking 
glatiramer acetate (41.7%) than by those taking interferons 
(83.1%). Of these medications, analgesics were the most fre-
quently consumed class of drug. Again, patients treated with 
glatiramer acetate reported consuming analgesics less fre-
quently than did those receiving an interferon (27.8%   versus 
78.3%; P , 0.001). Use of antidepressants was reported by 
Table 4 Treatment perceptions
Current treatment helps reduce relapse frequency 
  Totally agree 
  Partly agree 
  Partly disagree 
  Totally disagree 
  No opinion
 
100 (49.5%) 
80 (39.6%) 
12 (5.9%) 
4 (2.0%) 
6 (3.0%)
Current treatment helps slow disease progression 
  Totally agree 
  Partly agree 
  Partly disagree 
  Totally disagree 
  No opinion
 
72 (35.6%) 
100 (49.5%) 
18 (8.9%) 
3 (1.5%) 
9 (4.5%)
i live better with MS since starting treatment 
  Totally agree 
  Partly agree 
  Partly disagree 
  Totally disagree 
  No opinion
 
67 (33.2%) 
80 (39.6%) 
29 (14.4%) 
19 (9.4%) 
7 (3.5%)
i am more optimistic about my MS since starting treatment 
  Completely agree 
  Partly agree 
  Partly disagree 
  Completely disagree 
  No opinion
 
56 (27.7%) 
91 (45.0%) 
34 (16.8%) 
15 (7.4%) 
6 (3.0%)
Abbreviation: MS, multiple sclerosis.
0% 20% 40% 60% 80% 100%
No side effects
Other side-effects
General skin reactions
Digestive problems
Palpitations/hot flushes
Insomnia
Depression/low mood
Injection-site reactions
Irratibilty/mood swings
Flu-like state
Post-injection fatigue
Headache
Muscle pain
Figure 1 Patient-reported side effects.
Notes: Open bars, interferon-β (n = 166); filled bars, glatiramer acetate (n = 36).
better with their disease and felt more optimistic about it 
since starting therapy. Less than 10% totally disagreed with 
any of these statements.
Only ten patients reported experiencing no side effects 
attributable to treatment in the preceding months, and 
most reported multiple side effects (mean 5.0 ± 3.0). 
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05 0 100 150
 I try to live normally
and to forget my MS                                                 
Living with MS is a                                                           
 struggle every day
 It is impossible to 
have a normal life                                                           
No reply
Number of patients
Figure 2 impact of disease.
37 patients (18.3%) and sedative use by 26 (12.9%), with no 
difference between the treatment groups.
The majority of patients (n = 169; 83.7%) reported not 
being bothered by having to undergo regular blood tests for 
monitoring of their treatment, with only 18 patients (8.9%) 
claiming to be very or quite bothered by this.
impact of disease
Patients were asked how they considered that their disease 
affected their life. Around two thirds of the patients (n = 136) 
reported that they tried to live normally and forget their mul-
tiple sclerosis, whereas 21 patients (10.4%) considered that 
it was impossible for them to have a normal life (Figure 2). 
In order to assess impact of the treatment on quality of life, 
seven dimensions were evaluated on a scale ranging from 0 
(very considerable negative impact) to 10 (no impact). The 
median overall quality of life score was 6 (interquartile 
range 4–9; mean 6.05 ± 3.03). The item most affected was 
physical activity (median score 6 [3–10]). Patients treated 
with glatiramer acetate reported that their quality of life was 
somewhat less affected by treatment than patients treated with 
interferon-β preparations (Table 5), with a median overall 
quality of life score of 7 (5–10) versus 5 (4–9). A similar 
trend could be observed for most of the individual items of 
the scale (Table 5).
Eighty patients (39.6%) reported having to give up their 
regular activities due to their illness (Figure 3), and for more 
than ten days in 34 patients (16.8%). Among the 149 patients 
who were working, 46 (30.9%) had taken at least one day off 
work during the three months preceding the survey due to 
their illness, and 24 (16.1%) had taken more than ten days 
off (Figure 4). Forty-one patients using interferon-β (33.3%) 
and five patients using glatiramer acetate (19.2%) reported 
taking at least one day off work.
Psychometric properties of quality  
of life scale
Internal consistency of the quality of life scale was high, 
with a Cronbach’s α coefficient of 0.935. Pairwise correla-
tions of scores on each item of the scale were all significant 
(P . 0.05) and individual correlation coefficients ranged from 
0.543 between “professional activities” and “relationships/
sex life” to 0.847 between “physical activity” and “social 
life/leisure” (Table 6). Correlation coefficients . 0.60 are 
considered good and those .0.80 very good. Factorial 
analysis showed the scale to be unidimensional, with 94% 
of the explained variance in the data being accounted for by 
a single dimension with an Eigenvalue of 4.76. This was 
the only dimension to have an Eigenvalue . 1, which is 
the generally accepted threshold for relevance. Correlations 
between individual item scores and the factor score were 
all .0.75, indicating a good fit to the data.
Discussion
This study surveyed 202 patients with multiple sclerosis 
treated with an immunomodulatory agent for an   average 
of 3 years. The most widely used immunomodulatory 
treatment was interferon-β 1a intramuscularly. The distri-
bution of treatments used was consistent with the known 
market share of these medications at the time of the survey. 
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Over half of the patients reported that they had followed 
their neurologist’s advice in the choice of treatment and 
only 45% claimed to have had any input in the treatment 
decision. This suggests that the extent of patient empow-
erment in everyday clinical practice in France, at least 
at the time of the study, was relatively low, in spite of 
recognition that this is important. When patients did have 
a say in the choice of treatment, efficacy was the principal 
criterion of choice.
Adherence was assessed on the basis of patient self-
report. In the sample, 26.2% of patients reported that 
they had skipped medication at least once in the previous 
3 months, although for most of these no more than three 
doses had been missed. This is likely to be an underestimate 
due to the source of information, because patients may be 
unwilling to admit to themselves or to others that they are 
noncompliant, as indicated by the observation that most did 
not discuss the issue with their physician. More objective 
methods of collecting data on adherence, such as prescription 
claims surveys, would be useful to address this point. 
For example, the medication possession ratio represents 
the number of doses dispensed in relation to the dispensing 
period over a given time   period.16 The medication possession 
ratio has been evaluated in the PRISMS (Prevention of 
Relapses and Disability by Interferon beta-1a Subcutaneously 
in Multiple Sclerosis) trial of interferon-β 1a subcutaneously, 
a pivotal clinical trial where adherence may be expected to 
be high. In this trial, the medication possession ratio was 
78%, suggesting that patients were skipping one in four 
of their scheduled doses.17 Two recent prescription claims 
studies from the US also reported a medication possession 
ratio of around 0.75 for different immunomodulatory 
treatments used in everyday practice.18,19 A prospective study 
from Australia reported that 73% of patients missed doses 
over a mean follow-up period of 2.4 years.20
Two factors were identified as being important determi-
nants of adherence, ie, patient age and degree of informa-
tion about disease. The best informed and oldest patients 
were the most compliant. The survey also showed that half 
of the patients did not consider themselves well informed. 
A similar but not significant trend was also observed for 
better adherence in patients who considered themselves well 
informed about their treatment. The recent Global Adherence 
  Project21 used multivariate logistic analysis to identify factors 
independently related to adherence with immunomodula-
tory therapy in patients with multiple sclerosis. This study 
reported superior adherence in women compared with men, 
in patients earlier on in their disease course, and in patients 
who had more support from families and neurologists. The 
relationship between these factors and adherence was not 
evaluated in the present study.
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Figure 3 interference with activities of daily living. Data are expressed as days missed due to multiple sclerosis in the previous 3 months.
Notes: Gray columns, all patients (n = 202), professional activities or normal daily activities; black columns, patients in employment (n = 149), professional activities.
Table  5  impact  of  treatment  on  quality  of  life  according  to 
treatment
All interferon-β Glatiramer  
acetate
Total
Physical activity 6 (3–9) 8.5 (2.75–10) 6 (3–10)
Morale/mood 6 (3.75–9) 7 (6–10) 7 (4–9)
Social life/leisure 7 (3–9) 8 (3.75–10) 7 (3–9)
Professional activities 7 (3–10) 9.5 (4–10) 8 (3–10)
Relationships/sex life 8 (4.75–10) 7.5 (4–10) 8 (4–10)
Family/emotional life 8 (4–10) 8 (5–10) 8 (5–10)
Overall quality of life 5 (4–9) 7 (5–10) 6 (4–9)
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We failed to observe a significant difference in self-reported 
adherence rates between the four immunomodulatory 
treatments. Other studies have reported superior adherence 
to intramuscular interferon-β 1a than to subcutaneously 
administered treatments,19,21,22 and our study shows a trend 
in this direction. It is possible that the relatively low patient 
numbers limit the statistical power to demonstrate intergroup 
differences. Nevertheless, it is important to note that the 
consequences of missing a single dose of the four available 
immunomodulatory treatments is not the same, because 
different treatments are administered at different frequencies. 
Consequently, missing one injection of weekly intramuscular 
interferon-β 1a in a month corresponds to missing 25% of 
the scheduled dose, equivalent to missing seven injections of 
glatiramer acetate. For the 44 patients who reported missing 
between one and three injections in the previous 3 months, 
this corresponds to 8.3%–25.0% of the total planned 
intramuscular dose of interferon-β 1a, but only 0.1%–0.3% 
of the total planned dose of glatiramer acetate.
We also observed that 18% of patients interrupted their 
treatment for at least a week. This is a considerably lower 
rate than that previously reported in a large Canadian cohort, 
in which 33% of 846 patients treated with an interferon-β 
stopped treatment for at least one month.13 This difference may 
be due to under-reporting or to the fact that all patients in the 
survey had been on treatment for at least 3 months at the time 
of the study. Another important aspect of adherence, namely 
treatment persistence, cannot be addressed in this study for 
this same reason. However, much information has already 
been published on persistence with immunomodulatory treat-
ment for multiple sclerosis, showing this to be poor.9–13
Amongst the reasons for non adherence with treatment, 
forgetfulness was the most frequently cited, together with 
injection fatigue and side effects. These findings are consis-
tent with those of the Global Adherence Project on patient 
adherence.21 Even though efficacy was the primary criterion 
in selecting the treatment for multiple sclerosis, poor efficacy 
was not frequently cited as a reason for non adherence in our 
study, although it appears from other studies to be a major 
reason for treatment discontinuation.13,23 In this study, most of 
the patients thought that the treatment that they were taking 
reduced the frequency of relapses and slowed progression 
of the disease.
Given that side effects were cited as a reason for non 
adherence and that these differ between available immuno-
modulatory treatments, patient perceptions of side effects 
are also of relevance. Less than 5% of patients reported that 
their treatments had no side effects. Injection site reactions 
were reported more frequently with glatiramer acetate and 
influenza-like syndromes and post-injection fatigue more 
frequently with interferon-β, consistent with experience 
from clinical trials. Use of symptomatic medication for 
management of side effects, notably analgesics, was reported 
significantly more frequently in patients using interferon-β 
compared with those using glatiramer acetate.
Overall reported quality of life was somewhat less impaired 
in patients using glatiramer acetate than in those treated by 
interferon-β. This may reflect the lower tendency of glatiramer 
acetate to aggravate fatigue compared with interferon-β, as 
has been reported previously.3 The difference is unlikely to be 
accounted for by prescription of interferon-β to patients with 
more severe disease, given that EDSS scores were comparable 
across treatment groups. However, these findings should 
be interpreted with caution, because the treatment duration 
and previous history differed between the patients receiving 
interferon-β and those receiving glatiramer acetate.
The study also collected information on how well the 
patients considered themselves to be informed about their 
disease and its treatment. Fewer than half of the patients 
said that they were well informed about their disease. This 
is consistent with the desire expressed by half of the patients 
for more contact with their neurologist and their general 
practitioner. Considering that patient information seems to 
be important for optimizing adherence, it is important for 
neurologists to involve the patient as soon as treatment is 
started, and to give more adequate information about the 
Table 6 Correlation matrix of scores on seven items of the quality of life questionnaire
Variable Family/ 
emotional life
Morale/ 
mood
Social life/ 
leisure
Physical  
activity
Relationships/ 
sex life
6-professional  
activities
7-overall  
quality of life
Family/emotional life 1 0.757 0.695 0.582 0.653 0.565 0.804
Morale/mood 0.757 1 0.633 0.561 0.604 0.577 0.781
Social life/leisure 0.695 0.633 1 0.847 0.597 0.653 0.820
Physical activity 0.582 0.561 0.847 1 0.585 0.674 0.751
Relationships/sex life 0.653 0.604 0.597 0.585 1 0.543 0.720
Professional activities 0.565 0.577 0.653 0.674 0.543 1 0.746
Overall quality of life 0.804 0.781 0.820 0.751 0.720 0.746 1
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disease and its treatment, in particular about the potential 
impact on quality of life, which differs from one treatment 
to another. By taking into consideration patient perceptions 
of treatment in terms of efficacy, safety, and impact on 
quality of life, as well as involving patients more in sharing 
treatment decisions, the clinician can take a more personal 
interest in the individual patient. As a result, the patient may 
become more actively involved in managing the disease, and 
thus facilitate the chances of achieving the goal of optimal 
adherence with treatment.15
This survey collected data directly from patients using 
a questionnaire completed at home, and sent directly to 
the data analysis center. This methodological approach 
has both strengths and weaknesses. On the positive side, this 
approach should improve the spontaneity of patient replies 
compared with collecting the data through the physician. This 
approach also circumvents the mismatch between physician 
and patient perceptions of the disease and its impact.24 
On the negative side, reporting bias cannot be excluded. 
Adherence rates are likely to be underestimated, and there 
is no way of ascertaining the incidence of side effects and 
duration of sick leave. The response rate for neurologists is 
at first sight rather low (12.5%), but this is to be expected, 
given that around two thirds of practicing neurologists 
in France do not regularly manage patients with multiple 
sclerosis. Taking the 400 neurologists in the French Multiple 
  Sclerosis Observatory, who see almost all multiple sclerosis 
patients in France as the denominator, the response rate was 
around 45%. Nonetheless, it is possible that incomplete 
participation of neurologists introduces some selection bias. 
In addition, no information is available on patients who 
refused to participate and, again, this is an important source 
of potential selection bias.
It should also be noted that the survey was carried out 
before natalizumab became available for the treatment of 
multiple sclerosis in France. Seven of eight patients said that 
they would stay on their current treatment until a potential 
alternative would be available. The introduction of natali-
zumab and of the emerging oral therapies may be expected 
to influence patient perceptions and expectations of their 
treatments. The data collected in the present study will serve 
as a useful benchmark to measure the change in treatment 
perceptions as therapeutic opportunities evolve.
In conclusion, the more our patients are informed 
about their disease and its treatment, the higher the level of 
adherence that can be achieved. Neurologists would benefit 
from developing communication skills to improve patient 
involvement in the management of their disease.
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